Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis

Rheumatol Int. 2007 Dec;28(2):185-7. doi: 10.1007/s00296-007-0391-9. Epub 2007 Jul 11.

Abstract

It has been well known that anti-TNF drugs might increase lymphoma risk in rheumatoid arthritis (RA), where the rate of lymphoma has already been increased. However, unlike RA, an increased rate of lymphoma has not been reported in ankylosing spondylitis (AS). Hereby, we present a case with AS developing Hodgkin's lymphoma (HL) following 6 months of etanercept treatment. Pathological analysis revealed mixed cellular type of HL. Although we report a single case, it should be kept in mind that anti-TNF drugs might cause lymphoma development not only in RA, but also in AS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Etanercept
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / etiology*
  • Hodgkin Disease / pathology
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Male
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Spondylitis, Ankylosing / drug therapy*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept